Governmental or Regulatory Activity
Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling
NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Six Payer Trends Shaping Market Access in 2025
Market, trends qualifier, Access, Enrollment, 2025, payer, Shapes, payers, Artificial Intelligence
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
United States Food and Drug Administration, Makary, Vaccines, Ethics, Advisory Committees
Makary Sails Through Senate Confirmation Hearing for FDA Commissioner
Martin Makary, FDA, Senate confirmation hearing, vaccine advisory committee, drug reviews, ethics, staffing changes
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
Congressional Healthcare Reform Priorities Under Trump’s Second Term
ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care
Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions
Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration
Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings
Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration